NSC-370284 is a selective inhibitor of ten-eleven translocation 1 ( TET1 ) and 5-hydroxymethylcytosine ( 5hmC ). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5.
Storage Temp
Store at -20°C
Shipped In
Ice chest + Ice pads
Product Description
NSC-370284 is a selective inhibitor of ten-eleven translocation 1 ( TET1 ) and 5-hydroxymethylcytosine ( 5hmC ). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5
In Vitro
NSC-370284 (0-500 nM; 24 h or 48 h) inhibits the viability of MONOMAC-6, THP-1, KOCL-48 and KASUMI-1 acute myeloid leukemia (AML) cells via targeting STAT3/5. NSC-370284 significantly down-regulates the level of TET1 transcription. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: AML cell lines including MONOMAC-6, THP-1, KOCL-48, and KASUMI-1. Concentration: 0, 25, 50, 200 or 500 nM. Incubation Time: 24 h or 48 h. Result: Showed inhibitory for AML cells viability and TET1 transcription.
In Vivo
NSC-370284 (2.5 mg/kg; i.p., once daily for 10 days) improves the pathological morphologies in peripheral blood (PB), bone marrow (BM), spleen, and liver tissues in MLL-AF9 acute myeloid leukemia (AML) mice model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice . Dosage: 2.5 mg/kg. Administration: Intraperitoneal injection, once daily, for 10 days. Result: Significantly inhibited MLL-AF9 induced AML in secondary bone marrow transplantation (BMT) recipient mice.
